Severe intestinal dysbiosis is prevalent in primary Sjögren’s syndrome and is associated with systemic disease activity
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Altered microbial composition of the intestine, commonly referred to as dysbiosis, has been associated with several autoimmune diseases including primary Sjögren's syndrome (pSS). The aims of the current study were to study the intestinal microbial balance in pSS and to identify clinical features associated with dysbiosis. METHODS: Forty-two consecutive pSS patients and 35 age-matched and sex-matched control subjects were included in the study in an open clinic setting. Stool samples were analyzed for intestinal dysbiosis using a validated 16S rRNA-based microbiota test (GA-map™ Dysbiosis Test; Genetic Analysis, Oslo, Norway). Dysbiosis and severe dysbiosis were defined in accordance with the manufacturer's instructions. Patients were evaluated with regard to disease activity (European League Against Rheumatism (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI) and Clinical ESSDAI (ClinESSDAI)). In addition, patients were examined for laboratory and serological features of pSS as well as fecal calprotectin levels. Furthermore, patients were investigated regarding patient-reported outcomes for pSS (EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI)) and irritable bowel syndrome (IBS)-like symptoms according to the Rome III criteria. RESULTS: Severe dysbiosis was more prevalent in pSS patients in comparison to controls (21 vs 3%; p = 0.018). Subjects with pSS and severe dysbiosis had higher disease activity as evaluated by the ESSDAI total score (13 vs 5; p = 0.049) and the ClinESSDAI total score (12 vs 5; p = 0.049), lower levels of complement component 4 (0.11 vs 0.17 g/L; p = 0.004), as well as higher levels of fecal calprotectin (110 vs 33 μg/g; p = 0.001) compared to the other pSS patients. In contrast, severe dysbiosis among pSS patients was not associated with disease duration, IBS-like symptoms, or the ESSPRI total score. CONCLUSIONS: Severe intestinal dysbiosis is a prevalent finding in pSS and is associated both with clinical and laboratory markers of systemic disease activity as well as gastrointestinal inflammation. Further studies are warranted to elucidate a potential causative link between dysbiosis and pSS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of the microbiota in immunity and inflammation.
Belkaid, Y., & Hand, T. W. (2014) · Cell · doi:10.1016/j.cell.2014.03.011 · Cited by 5,385
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
The microbiota in adaptive immune homeostasis and disease
Honda, K., & Littman, D. R. (2016) · Nature · doi:10.1038/nature18848 · Cited by 1,846 · cited 1×
“This interaction has been suggested to have profound effects on both the local and systemic immune system [11], and may both curtail and amplify local and systemic inflammatory disease [12].”
BackgroundGut microbiota and IBD: causation or correlation?
Ni, J., Wu, G. D., Albenberg, L., & Tomov, V. T. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.88 · Cited by 1,778
Willing, B. P., Dicksved, J., Halfvarson, J., Andersson, A. F., Lucio, M., Zheng, Z., Järnerot, G., Tysk, C., Jansson, J. K., & Engstrand, L. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.08.049 · Cited by 1,032
López, P., de Paz, B., Rodríguez-Carrio, J., Hevia, A., Sánchez, B., Margolles, A., & Suárez, A. (2016) · Scientific Reports · doi:10.1038/srep24072 · Cited by 262 · cited 1×
“One hypothesis, however, is that an imbalance in the gut microbiota in the genetically susceptible individual leads to an increase in TH17 cells in the gut [38], which in turn enter the circulation and migrate to the exocrine glands, and possibly other tissues, to drive inflammation and development of both exocrine di…”
BackgroundBennet, S. M. P., Böhn, L., Störsrud, S., Liljebo, T., Collin, L., Lindfors, P., Törnblom, H., Öhman, L., & Simrén, M. (2018) · Gut · doi:10.1136/gutjnl-2016-313128 · Cited by 225
Using Corticosteroids to Reshape the Gut Microbiome: Implications for Inflammatory Bowel Diseases
Huang, E. Y., Inoue, T., Leone, V. A., Dalal, S., Touw, K., Wang, Y., Musch, M. W., Theriault, B., Higuchi, K., Donovan, S., et al. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000332 · Cited by 204 · cited 1×
“Indeed, some animal studies have indicated a direct effect of GCs on the microbial balance in the intestine [33, 34].”
BackgroundInfluence of Proton-Pump Inhibitors on the Luminal Microbiota in the Gastrointestinal Tract
Tsuda, A., Suda, W., Morita, H., Takanashi, K., Takagi, A., Koga, Y., & Hattori, M. (2015) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2015.20 · Cited by 164 · cited 1×
“Of interest, treatment with PPI, NSAIDs, or AMA was not associated with severe intestinal dysbiosis in our study, reminiscent of findings in previous studies [35, 36].”
Result
Cited by
The microbiome in autoimmune diseases
De Luca, F., & Shoenfeld, Y. (2018) · Clinical and Experimental Immunology · doi:10.1111/cei.13158 · Cited by 510
Wang, Y., Wei, J., Zhang, W., Doherty, M., Zhang, Y., Xie, H., Li, W., Wang, N., Lei, G., & Zeng, C. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.104055 · Cited by 165
Klingberg, E., Magnusson, M. K., Strid, H., Deminger, A., Ståhl, A., Sundin, J., Simrén, M., Carlsten, H., Öhman, L., & Forsblad-d’Elia, H. (2019) · Arthritis Research & Therapy · doi:10.1186/s13075-019-2018-4 · Cited by 101
Ming, X., Chen, N., Ray, C., Brewer, G., Kornitzer, J., & Steer, R. A. (2018) · Child Neurology Open · doi:10.1177/2329048x18786799 · Cited by 64
Metadata
- Authors
- Mandl, T., Marsal, J., Olsson, P., Ohlsson, B., & Andréasson, K.
- Venue
- Arthritis Research & Therapy
- Published
- 2017-10-24
- Volume
- 19
- Issue
- 1
- Pages
- 237-237
- ISSN
- 1478-6354 (ISSN-L)
- 1478-6362
- OpenAlex
- W2766999422
- Cited by
- 140
- References
- 9
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.